SC
RARE icon

SummitTX Capital’s Ultragenyx Pharmaceutical RARE Stock Holding History

SummitTX Capital’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Buy
374,270
+26,510
+8% +$658K 0.32% 70
2026
Q1 		$7.29M Buy
+347,760
New +$7.83M 0.23% 106
2025
Q2 		– Sell
-20,085
Closed -$727K – 972
2025
Q1 		$727K Buy
+20,085
New +$836K 0.03% 457

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

SummitTX Capital's RARE Position: Q2 2026 in Review

SummitTX Capital increased its Ultragenyx Pharmaceutical (RARE) stake by 7.6% in Q2 2026, buying an estimated $658K and bringing the position to 374,270 shares worth $12.5M. The position accounts for 0.32% of the portfolio, ranked #70.

SummitTX Capital first reported a position in RARE in Q1 2025 and has held it in 3 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • SummitTX Capital held 374,270 shares of Ultragenyx Pharmaceutical worth $12.5M as of Q2 2026.
  • SummitTX Capital bought 26,510 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $658K.
  • Ultragenyx Pharmaceutical made up 0.32% of SummitTX Capital's portfolio in Q2 2026, its #70 holding.
  • SummitTX Capital first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and has held it in 3 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.